From the Journals
FDA & Government News
Obesity Medications Get New Guidance
Panel outlines pharmacotherapy roles across obesity complications and long-term weight management.
Recent guidance evaluates the efficacy of newer incretin-based therapies for treating obesity, particularly semaglutide and tirzepatide, which show significant weight loss and improvements in obesity-related conditions. In numerous studies, semaglutide demonstrated substantial weight reduction and reduced cardiovascular mortality, while tirzepatide showed similar successful outcomes with fewer adverse events. Recommendations include using these therapies for patients with obesity-related conditions like sleep apnea and type 2 diabetes, emphasizing a multimodal approach in management.
